



04772 U.S. PTO

Please type a plus sign (+) inside this box ☐

Attorney Docket P1192-2C1

PATENT

Express Mail Number: Express Mail Label No. EV 351 932 477 US  
Date of Deposit: March 2, 2004

22141 U.S. PTO  
10/791618



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop PATENT APPLICATION  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)**

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

**Sherman Fong, Alameda, California**  
**Audrey Goddard, San Francisco, California**  
**Kenneth J. Hillan, San Francisco, California**  
**Iris Roth, South San Francisco, California**  
**William I. Wood, Hillsborough, California**

Title: **NOVEL POLYPEPTIDES AND NUCLEIC ACIDS ENCODING BOLEKINE**

**1. Type of Application**

- ☐ This application is for an original, non-provisional application.
- ☐ This is a non-provisional application claiming priority to provisional application no. \_\_\_\_\_, filed \_\_\_\_\_ the entire disclosure of which is hereby incorporated by reference.
- ☒ This is a ☐ continuation-in-part ☒ continuation ☐ divisional application claiming priority to application Serial Number 09/816,920, filed March 22, 2001, which claims priority to PCT/US00/05841, filed March 2, 2000, and PCT/US00/04341, filed February 18, 2000, and PCT/US99/05028, filed March 8, 1999, and 60/083,336, filed April 27, 1998, and 60/064,249, filed November 3, 1997, the entire disclosure of which is hereby incorporated by reference.

**2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b) (Non-provisional )**

91 pages of specification  
2 pages of claims  
1 page(s) of abstract  
8 sheet(s) of drawings  
☒ formal ☐ informal

**3. Declaration or Oath**

*(for new and CIP applications; also for Cont./Div. where inventor(s) are being added)*  
\_\_\_\_ An executed declaration of the inventor(s) [ ] is enclosed [ ] will follow.

*(for Cont./Div. where inventorship is the same or inventor(s) being deleted)*  
X A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).

*(for Cont./Div. where inventor(s) being deleted)*  
\_\_\_\_ A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).

**4. Assignment**

*(for new and CIP applications)*  
\_\_\_\_ An Assignment of the invention to GENENTECH, INC. [ ] is enclosed with attached Recordation Form Cover Sheet [ ] will follow.

*(for cont./div.)*  
X The prior application is assigned of record to Genentech, Inc. (Reel/Frame 011717/0254, Recorded on 07/05/2001)

**5. Amendments (for continuation and divisional applications)**

\_\_\_\_ Cancel in this application original claims \_\_\_\_ of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

\_\_\_\_ A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

**6. Fee Calculation (37 CFR 1.16)**

The fee has been calculated as follows:

CLAIMS FOR FEE CALCULATION					
Number Filed		Number Extra		Rate	Basic Fee 37 CFR 1.16(a)
					\$770.00
Total Claims	10	- 20 =	0	X \$18.00	\$0.00
Independent Claims	5	- 3 =	2	X \$86.00	\$172.00
Multiple dependent claim(s), if any				+ \$290.00	\$0.00
Filing Fee Calculation					\$942.00

**7. Method of Payment of Fees**

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$942.00. **A duplicate copy of this transmittal is enclosed.**

**8. Authorization to Charge Additional Fees**

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. **A duplicate copy of this transmittal is enclosed.**

**9. Additional Papers Enclosed**

- ☐ Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations  
☒ Letter and REQUEST TO USE COMPUTER-READABLE SEQUENCE LISTING UNDER 37 CFR §1.821(e), including paper copy of sequence listing.  
☐ A new Power of Attorney or authorization of agent.  
☒ Other: Postcard.

**10. Maintenance of Copendency of Prior Application (for continuation and divisional applications)**

*[This item must be completed and the necessary papers filed in the prior application if the period set in the prior application has run]*

- \_\_\_\_\_ A petition, fee and/or response has been filed to extend the term in the pending prior application until  
 \_\_\_\_\_ A copy of the petition for extension of time in the **prior** application is attached.

**11. Correspondence Address:**

X Address all future communications to:

Attn: David A. Carpenter Ph.D.  
Customer No: 09157

Respectfully submitted,  
GENENTECH, INC.

Date: March 2, 2004

By: 

David A. Carpenter  
Reg. No: 45,945  
Telephone No. (650) 225-3733

**CUSTOMER NO: 09157**